company background image
4569 logo

KYORIN Pharmaceutical TSE:4569 Stock Report

Last Price

JP¥1.69k

Market Cap

JP¥97.3b

7D

1.1%

1Y

-2.6%

Updated

12 Jun, 2024

Data

Company Financials +

KYORIN Pharmaceutical Co., Ltd.

TSE:4569 Stock Report

Market Cap: JP¥97.3b

4569 Stock Overview

Through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally.

4569 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health5/6
Dividends3/6

KYORIN Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for KYORIN Pharmaceutical
Historical stock prices
Current Share PriceJP¥1,692.00
52 Week HighJP¥1,880.00
52 Week LowJP¥1,646.00
Beta-0.066
1 Month Change-3.48%
3 Month Change-5.16%
1 Year Change-2.65%
3 Year Change-3.37%
5 Year Change-11.18%
Change since IPO14.40%

Recent News & Updates

Recent updates

Shareholder Returns

4569JP PharmaceuticalsJP Market
7D1.1%-0.7%0.3%
1Y-2.6%-0.7%17.5%

Return vs Industry: 4569 underperformed the JP Pharmaceuticals industry which returned -0.5% over the past year.

Return vs Market: 4569 underperformed the JP Market which returned 19.8% over the past year.

Price Volatility

Is 4569's price volatile compared to industry and market?
4569 volatility
4569 Average Weekly Movement2.2%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement3.9%
10% most volatile stocks in JP Market7.5%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 4569 has not had significant price volatility in the past 3 months.

Volatility Over Time: 4569's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,138Yutaka Ogiharawww.kyorin-pharm.co.jp

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis therapeutic agents; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents, intermediates, and other products.

KYORIN Pharmaceutical Co., Ltd. Fundamentals Summary

How do KYORIN Pharmaceutical's earnings and revenue compare to its market cap?
4569 fundamental statistics
Market capJP¥97.32b
Earnings (TTM)JP¥5.32b
Revenue (TTM)JP¥119.53b

18.3x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4569 income statement (TTM)
RevenueJP¥119.53b
Cost of RevenueJP¥68.12b
Gross ProfitJP¥51.41b
Other ExpensesJP¥46.09b
EarningsJP¥5.32b

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 31, 2024

Earnings per share (EPS)92.64
Gross Margin43.01%
Net Profit Margin4.45%
Debt/Equity Ratio15.9%

How did 4569 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

56%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.